Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab vs Capecitabine Maintenance in High-Risk Nasopharyngeal Carcinoma
NCT07392320Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2026
- Primary completion
- Feb 2031
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of penpulimab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started Feb 2026; status: recruiting.
02
Drugs
penpulimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07392320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07392320.